These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 33662858)

  • 1. Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study.
    Zhang Y; Staker E; Cutter G; Krieger S; Miller AE
    Mult Scler Relat Disord; 2021 May; 50():102856. PubMed ID: 33662858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.
    Vogel AC; Schmidt H; Loud S; McBurney R; Mateen FJ
    Mult Scler Relat Disord; 2020 Nov; 46():102512. PubMed ID: 32977074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.
    Azimzadeh M; Möhn N; Ghane Ezabadi S; Moghimi Esfandabadi Z; Soleimani A; Ranjbar E; Jahromi M; Seyedebrahimi R; Skripuletz T; Moharrami Kasmaie F
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach.
    Hamdy SM; Abdel-Naseer M; Shehata HS; Hassan A; Elmazny A; Shalaby NM; Abokrysha NT; Kishk NA; Nada MAF; Ahmed SM; Hegazy MI; Mekkawy D; Mourad HS; Abdelalim A; Berger T
    Ther Clin Risk Manag; 2020; 16():651-662. PubMed ID: 32801722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of COVID-19 disease and its effect on disability in patients with multiple sclerosis and other allied demyelinating disorders.
    Dhamija K; Bhatia R; Srivastava MVP; Singh G; Bali P; Rani A
    Clin Neurol Neurosurg; 2024 Feb; 237():108160. PubMed ID: 38350173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
    Portaccio E; Fonderico M; Hemmer B; Derfuss T; Stankoff B; Selmaj K; Tintorè M; Amato MP
    Mult Scler; 2022 Jan; 28(1):132-138. PubMed ID: 33764197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
    Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
    CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs.
    Otero-Romero S; Ascherio A; Lebrun-Frénay C
    Curr Opin Neurol; 2021 Jun; 34(3):322-328. PubMed ID: 33709979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.
    Salter A; Fox RJ; Newsome SD; Halper J; Li DKB; Kanellis P; Costello K; Bebo B; Rammohan K; Cutter GR; Cross AH
    JAMA Neurol; 2021 Jun; 78(6):699-708. PubMed ID: 33739362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 in a temporal relation to the onset of multiple sclerosis.
    Fragoso YD; Pacheco FAS; Silveira GL; Oliveira RA; Carvalho VM; Martimbianco ALC
    Mult Scler Relat Disord; 2021 May; 50():102863. PubMed ID: 33662859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis.
    Uher T; Krasensky J; Malpas C; Bergsland N; Dwyer MG; Kubala Havrdova E; Vaneckova M; Horakova D; Zivadinov R; Kalincik T
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33727311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis.
    Dziedzic A; Saluk-Bijak J; Miller E; Niemcewicz M; Bijak M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
    Achiron A; Dolev M; Menascu S; Zohar DN; Dreyer-Alster S; Miron S; Shirbint E; Magalashvili D; Flechter S; Givon U; Guber D; Stern Y; Polliack M; Falb R; Gurevich M
    Mult Scler; 2021 May; 27(6):864-870. PubMed ID: 33856242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The COVID-19 Pandemic Experience in Multiple Sclerosis: The Good, the Bad and the Neutral.
    Morris-Bankole H; Ho AK
    Neurol Ther; 2021 Jun; 10(1):279-291. PubMed ID: 33855692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort.
    van Kempen ZLE; Strijbis EMM; Al MMCT; Steenhuis M; Uitdehaag BMJ; Rispens T; Killestein J
    JAMA Neurol; 2021 Jul; 78(7):880-882. PubMed ID: 33929488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.
    Alborghetti M; Bellucci G; Gentile A; Calderoni C; Nicoletti F; Capra R; Salvetti M; Centonze D
    Curr Neuropharmacol; 2022; 20(1):107-125. PubMed ID: 33784961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive performance shows domain specific associations with regional cortical thickness in multiple sclerosis.
    Stellmann JP; Wanke N; Maarouf A; Gellißen S; Heesen C; Audoin B; Gold SM; Zaaraoui W; Poettgen J
    Neuroimage Clin; 2021; 30():102606. PubMed ID: 33744503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [MSProDiscuss - Development of a Digital Anamnesis Tool to Identify Disease Progression in Multiple Sclerosis].
    Inojosa H; Akgün K; Haacke K; Ziemssen T
    Fortschr Neurol Psychiatr; 2021 Jul; 89(7-08):374-381. PubMed ID: 33723837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
    Kelly H; Sokola B; Abboud H
    J Neuroimmunol; 2021 Jul; 356():577599. PubMed ID: 34000472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demyelination as a result of an immune response in patients with COVID-19.
    Shabani Z
    Acta Neurol Belg; 2021 Aug; 121(4):859-866. PubMed ID: 33934300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.